WO2026013624 - DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2026/013624
Publication Date
15.01.2026
International Application No.
PCT/IB2025/057021
International Filing Date
10.07.2025
Title **
[English]
DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
[French]
AGENTS D'ARNI DOUBLE BRIN, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
Applicants **
NOVARTIS AG
HUNZIKER, Juerg
Inventors
BROUSSEAU, Margaret Elizabeth
COUGHLIN, Shaun Robert
GHATAK, Payel
HAEMMIG, Stefan
HAGEN, Caitlin Jeanette
HUANG, Zhihong
TAN, Ge
WEILER, Jan
Priority Data
63/670,342
12.07.2024
US
63/786,760
10.04.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 20031 | |
| EPO | Filing, Examination, Granting | 637817 | |
| Japan | Filing, Examination, Granting | 7160 | |
| South Korea | Filing, Examination, Granting | 31756 | |
| USA | Filing, Examination, Granting | 108340 |
Total:
805,104
Contact Us
Abstract[English]
Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), for example, human HMGCR, compositions including the same, and methods of treatment using the same.[French]
L'invention concerne, entre autres, des agents d'ARNi double brin (dsRNAi) inhibant l'expression de 3-hydroxy-3-méthylglutaryl-CoA réductase (HMGCR), par exemple, le HMGCR humain, des compositions les comprenant, et des méthodes de traitement les utilisant.